

Erratum to: Neuropathy Associated with Hereditary Transthyretin Amyloidosis—Diagnosis and Management

Saša A Živković

Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA



Citation: *touchREVIEWS in Neurology*. 2020;17(1): [online only]

Erratum to: *US Neurology*. 2020;16(2):103–9
DOI: <https://doi.org/10.17925/USN.2020.16.2.103>


In the originally published article there was an error in *Table 4*. The efficacy of patisiran was incorrectly given as “mNIS+7: 80.9 versus 74.6 with placebo; Norfolk QOL-DN: 59.6 versus 55.4”; this should read “mNIS+7: 34 points better than placebo; Norfolk QOL-DN: 21.1 points better than placebo”. The “Concerns” of patisiran should also read “Local extravasation may cause irritation”. This has been corrected online, and *Table 4* has been corrected below. 

Table 4: Currently available treatments for ATTR

Drug	Approval status	Dosing	Efficacy	Concerns
Inotersen (Tegsedi®, Akcea Therapeutics, Boston, MA, USA)	PN: approved	300 mg weekly SC	mNIS+7: 19.7 points better than placebo; Norfolk QOL-DN: 11.7 points better than placebo	Thrombocytopenia, glomerulonephritis
Patisiran (Onpattro®, Alnylam Pharmaceuticals, Cambridge, MA, USA)	PN: approved	0.3 mg/kg every 3 weeks IV	mNIS+7: 34 points better than placebo; Norfolk QOL-DN: 21.1 points better than placebo	Local extravasation may cause irritation
Tafamidis (Vyndaqel® and Vyndamax® Pfizer, New York, NY, USA)	PN: stage I in EU, Brazil, Japan	20 mg PO	PN: more NIS-LL responders (45.3% versus 29.5%)	
	CM: approved for hATTR and wtATTR	80 mg PO*	CM: lower mortality (29.5% versus 42.9%)	
Diflunisal (Dolobid®, Merck & Co., Inc., Kenilworth, NJ, USA)	Off label	250 mg BID PO	29.7% with stable NIS+7 after 2 years (versus 9.4% with placebo)	Hypertension, nephropathy, gastrointestinal bleeding
AG10	Experimental	400/800 mg PO	Pending	Experimental medication

*Also available as a similar formulation of the same medication dosed at 61 mg daily (Vyndamax).

ATTR = transthyretin amyloidosis; BID = twice daily (bis in die); CM = cardiomyopathy; hATTR = hereditary transthyretin amyloidosis; IV = intravenous; mNIS+7 = modified Neuropathy Impairment Score; NIS-LL = Neuropathy Impairment Score-Lower Limb; PN = peripheral neuropathy; PO = by mouth (per os); QOL-DN = Quality of Life-Diabetic Neuropathy; SC = subcutaneous; wtATTR = wild-type transthyretin amyloidosis.